期刊文献+

糖链抗原对早期胰腺癌诊断价值 被引量:4

原文传递
导出
摘要 目的探讨糖链抗原(carbohydrate antigen,CA)19-9在胰腺癌早期诊断中价值。方法胰腺癌患者35例(观察组)与同期40名健康体检者(对照组),应用化学发光免疫分析法检测2组血清CA19-9水平,比较2组CA19-9水平及阳性率,并分析不同分期胰腺癌患者血清CA19-9水平变化情况。结果观察组血清CA19-9水平、CA19-9阳性率高于对照组(P<0.05);随胰腺癌分期增加,患者CA19-9水平增高,但不同分期患者CA19-9水平比较差异无统计学意义(P>0.05)。结论 CA19-9可作为诊断早期胰腺癌及判断病情分期的指标。
作者 颜伟 张克难
出处 《中华实用诊断与治疗杂志》 2012年第6期581-582,共2页 Journal of Chinese Practical Diagnosis and Therapy
作者简介 颜伟(1979年-),男,硕士,主治医师,研究方向:胃肠肿瘤的诊断与治疗。 通讯作者:张克难(1964年~),男,硕士,主任医师,研究方向:胃肠肿瘤的诊断与治疗,E—mail:25347410@qq.com。
  • 相关文献

参考文献6

二级参考文献40

  • 1Liao, Quan,Zhao, Yu-Pei,Yang, Ying-Chi,Li, Li-Jun,Long, Xiao,Han, Shao-Mei.Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head[J].Hepatobiliary & Pancreatic Diseases International,2007,6(6):641-645. 被引量:27
  • 2陈杰 刘复生 等.胰腺肿瘤.肿瘤病理学[M].北京:北京医科大学协合医科大学联合出版社,1997.951-973.
  • 3沈魁 黄志强.胰腺癌.现代腹部外科学[M].长沙:湖南科学技术出版社,1994.597-611.
  • 4肖锡宾 万德森.肿瘤临床诊断与标志物检查.临床肿瘤病学[M].北京:科学出版社,1999.52.
  • 5伊伯元.放谢免疫分析在医学中的应用[M].北京:原子能出版社,1991.332.
  • 6Hayashi N, Nakamori S,Okami J,et al. Asscciation between expression levels of CA 19-9 and N-acetylglucosaminee-beta; 1,3-galactosyltransferase 5gene in human pancreatic cancer tissun[ J ]. Pathobiology, 2003,71 ( 1 ): 26~34.
  • 7Macchia V, Gargiulo M. Cyclic AMP-dependent secretion of CA 19-9 by LS174T human colon carcinoma cells[ J]. Oncol Rep, 2002, 9 (2): 387 ~391.
  • 8元雄良治.肿瘤标志物在癌诊断的灵敏度及特异度[J].日本临床,1996,54(6):121-125.
  • 9Kim HJ,Lee KT, Kim SH,et al. Differential diagnosis of intrahepatic bile duct dilatation without demonstrable mass on ultrasonography or CT: Benign versus malignancy [ J ]. J Gastroenterol Hepatol.2003, 18 ( 11 ): 1 287 ~1292.
  • 10Kokhanenko NIU, Ignashov AM, Varga EV, et al. Role of the tumor markers CA 19-9 and carcinoembryonic antigen(CEA)in diagnosis, treatment and prognosis of pancreatic cancer[J].Vopr 0nkol.2001,47(3) :294~ 297.

共引文献111

同被引文献32

  • 1Chiara Tosolini,Christoph W Michalski,Jrg Kleeff.Response evaluation following neoadjuvant treatment of pancreatic cancer patients[J].World Journal of Gastrointestinal Surgery,2013,5(2):12-15. 被引量:7
  • 2闫慧明,郭艳丽,郑启昌,卢昕,马剑方.应用组织芯片技术研究uPA和uPAR在胰腺癌中的表达[J].山西医科大学学报,2004,35(5):455-457. 被引量:3
  • 3周桂霞,马林,刘永雄.放射性粒子治疗胰腺癌的研究进展[J].中华肝胆外科杂志,2004,10(12):862-864. 被引量:14
  • 4张福君,吴沛宏,赵明,黄金华,范卫君,顾仰葵,刘健,张亮,卢鸣剑.CT导引下^(125)I粒子植入治疗胰腺癌[J].中华医学杂志,2006,86(4):223-227. 被引量:120
  • 5Pedrazzoli S, Beger H G, Obertop H, et al. A surgical and pathological based classification of resective treatment of pancreatic cancer. Summary of an international workshop on surgical procedures in pancreatic cancer[J]. Dig Surg, 1999,16 (4):337- 345.
  • 6Farnell M B, Pearson R K, Sarr M G, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma[J]. Surgery, 2005, 138(4) :618-628.
  • 7Nagino M, Nimura Y. Dose "extended" surgery for pancreatic head adenocarcinoma have survival impact? [J]. Nihon Geka Gakkai Zasshi,2006,107(4) : 173-176.
  • 8Kayahara M, Funaki K, Tajima H, etal. Surgical implication of micrometastasis for pancreatic cancer[J]. Pancreas, 2010, 39 (6) :884- 888.
  • 9Bogoevski D, Yekebas E F, Schurr P, etal. Mode of spread in the early phase of lymphatic metastasis in pancreatic ductal adenocarcinoma : prognostic significance of nodal microinvolvement[J]. Ann Surg, 2004,240 (6) : 993-1000.
  • 10Pour P M, Bell R H, Batra S K. Neural invasion in the staging of pancreatic cancer[J]. Pancreas,2003,26(4) :322- 325.

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部